nannamom
Admin
Number of posts : 2210
Age : 65
Humor : Once you choose hope, anything’s possible. -Christopher Reeve
Registration date : 2008-11-09
 | | Subject: Good news for Suboxone patients within the OPT Thu 06 Dec 2012, 10:24 am | |
| Good morning everyone,
There is good news for those of you who may attend a Suboxone within the OPT setting. For those of you who aren't sure of what the OPT stands for, it is for patients who obtain their Suboxone in the clinic setting. A lot of Methadone clinics also carry Suboxone giving patients within the clinic system and choice between Suboxone and Methadone. Until now patients attending the OPT had to dose at the clinic every day until in treatment for a certain length of time to earn take home status of Suboxone just like methadone.
Beginning January 7, 2013 that all changes. Read below:1
DEPARTMENT OF HEALTH AND HUMAN SERVICES
42 CFR Part 8
RIN 0930-AA14
Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Proposed
Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combination as
Used in Approved Opioid Treatment Medications
AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA),
Department of Health and Human Services (HHS)
ACTION: Final Rule
SUMMARY: This final rule amends the federal opioid treatment program regulations by
modifying the dispensing requirements for buprenorphine and buprenorphine combination
products approved by the Food and Drug Administration (FDA) for opioid dependence and used
in federally certified and registered opioid treatment programs. In particular, this rule would
allow opioid treatment programs more flexibility in dispensing take-home supplies of
buprenorphine—removing restrictions on the time a patient needs to be in treatment in order to
receive take-home supplies—after the assessment and documentation of a patient’s responsibility
and stability to receive opioid addiction treatment medication. Opioid treatment programs that
use these products in the treatment of opioid dependence will continue to adhere to all other
federal treatment standards established for methadone.
FOR FURTHER INFORMATION CONTACT: Nicholas Reuter, Center for Substance
Abuse Treatment (CSAT), Division of Pharmacologic Therapies, SAMHSA,
1 Choke Cherry Road, Room 2-1063, Rockville, MD 20857, (240) 276-2716, e-mail:
Nicholas.Reuter@samhsa.hhs.gov.For those of you who would like to read a copy of the full press release, let me know and I will be happy to provide you the information. | |
|
